CO2022017622A2 - Inhibidores de quinasa nek7 - Google Patents

Inhibidores de quinasa nek7

Info

Publication number
CO2022017622A2
CO2022017622A2 CONC2022/0017622A CO2022017622A CO2022017622A2 CO 2022017622 A2 CO2022017622 A2 CO 2022017622A2 CO 2022017622 A CO2022017622 A CO 2022017622A CO 2022017622 A2 CO2022017622 A2 CO 2022017622A2
Authority
CO
Colombia
Prior art keywords
nek7
compounds
kinase inhibitors
activity
methods
Prior art date
Application number
CONC2022/0017622A
Other languages
English (en)
Inventor
David James Bearss
Iii John Sai Keong Kauwe
Alexis Henri Abel Mollard
Original Assignee
Halia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Halia Therapeutics Inc filed Critical Halia Therapeutics Inc
Publication of CO2022017622A2 publication Critical patent/CO2022017622A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Se proporcionan compuestos que tienen actividad como inhibidores de NEK7. Los compuestos tienen la Estructura (I): (I) (I) o una sal, estereoisómero o profármaco farmacéuticamente aceptable de los mismos, caracterizado porque A, X, Y, R1, R2, R3, R4 y R5 son como se definen aquí. También se proporcionan métodos asociados con la preparación y el uso de los compuestos, composiciones farmacéuticas que comprenden los compuestos y métodos para modular la actividad del inflamasoma NLRP3.
CONC2022/0017622A 2020-05-08 2022-12-06 Inhibidores de quinasa nek7 CO2022017622A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063022159P 2020-05-08 2020-05-08
US202163170761P 2021-04-05 2021-04-05
PCT/US2021/031394 WO2021242505A1 (en) 2020-05-08 2021-05-07 Inhibitors of nek7 kinase

Publications (1)

Publication Number Publication Date
CO2022017622A2 true CO2022017622A2 (es) 2022-12-20

Family

ID=77774963

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0017622A CO2022017622A2 (es) 2020-05-08 2022-12-06 Inhibidores de quinasa nek7

Country Status (13)

Country Link
US (3) US11161852B1 (es)
EP (1) EP4146348A1 (es)
JP (1) JP2023524597A (es)
KR (1) KR20230008763A (es)
CN (1) CN115843272A (es)
AU (1) AU2021280893A1 (es)
BR (1) BR112022022669A2 (es)
CA (1) CA3182276A1 (es)
CO (1) CO2022017622A2 (es)
IL (1) IL297979A (es)
MX (1) MX2022013984A (es)
TW (1) TW202208356A (es)
WO (1) WO2021242505A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021242505A1 (en) * 2020-05-08 2021-12-02 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
WO2024048519A1 (ja) * 2022-08-29 2024-03-07 日本たばこ産業株式会社 ピラゾロピリミジン化合物及びその医薬用途
WO2024059200A1 (en) * 2022-09-14 2024-03-21 Halia Therapeutics, Inc. Nek7 inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
AP2011005674A0 (en) 2008-09-25 2011-04-30 Boehringer Ingelheim Int Sulfonyl compounds which selectively modulate the CB2 receptor.
JP2013502429A (ja) 2009-08-19 2013-01-24 アムビト ビオスシエンセス コルポラチオン ビアリール化合物及びその使用方法
JP2013525308A (ja) 2010-04-16 2013-06-20 キュリス，インコーポレイテッド Ｋ−ｒａｓ変異を有する癌の治療
CN104093312B (zh) 2012-01-12 2017-04-26 巴斯夫欧洲公司 除草的异噁唑并[5,4‑b]吡啶类
ES2646019T3 (es) 2013-05-14 2017-12-11 Nerviano Medical Sciences S.R.L. Derivados de 6-amino-7-deaza-purina, proceso para su preparación y su uso como inhibidores de cinasa
WO2016075224A1 (en) 2014-11-14 2016-05-19 Nerviano Medical Sciences S.R.L. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
MX2018004359A (es) 2015-10-09 2018-05-01 Abbvie Sarl Pirazolo [3,4-b] piridin-6-carboxamidas n-sulfoniladas y metodo de uso.
US10167703B2 (en) 2016-03-31 2019-01-01 Saudi Arabian Oil Company Optimal well placement under constraints
SI3472165T1 (sl) 2016-06-21 2024-02-29 Nerviano Medical Sciences S.R.L., N-(substituirani fenil)-sulfonamidni derivati kot inhibitorji kinaz
KR20190028540A (ko) 2016-07-20 2019-03-18 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Perk 억제제로서의 이소퀴놀린 유도체
PE20210050A1 (es) 2017-11-09 2021-01-08 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida
IL277408B1 (en) 2018-04-05 2024-04-01 Merck Patent Gmbh Heteroaryl compounds as IRAK type II inhibitors and their use
CN111646995B (zh) 2019-03-04 2023-03-21 四川大学 4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途
CN112552302B (zh) * 2019-09-26 2022-05-13 深圳市塔吉瑞生物医药有限公司 取代的芳香稠合环衍生物及其组合物及用途
AU2020436612A1 (en) 2020-03-16 2022-09-01 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia
WO2021242505A1 (en) * 2020-05-08 2021-12-02 Halia Therapeutics, Inc. Inhibitors of nek7 kinase

Also Published As

Publication number Publication date
WO2021242505A1 (en) 2021-12-02
CA3182276A1 (en) 2021-12-02
MX2022013984A (es) 2023-01-30
JP2023524597A (ja) 2023-06-12
EP4146348A1 (en) 2023-03-15
CN115843272A (zh) 2023-03-24
TW202208356A (zh) 2022-03-01
IL297979A (en) 2023-01-01
US20220064173A1 (en) 2022-03-03
US11161852B1 (en) 2021-11-02
AU2021280893A1 (en) 2023-01-05
US11713321B2 (en) 2023-08-01
KR20230008763A (ko) 2023-01-16
BR112022022669A2 (pt) 2023-01-17
US20230416259A1 (en) 2023-12-28
US20210355130A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
CO2022017622A2 (es) Inhibidores de quinasa nek7
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
CO2022019131A2 (es) Inhibidores de la quinasa nek7
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
CR20160205A (es) Inhibidores de kras g12c
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
UY28979A1 (es) Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3
CL2009000085A1 (es) Compuestos derivados de sulfonamida sustituida, modulares de receptores de bradiquinina; proceso para su preparacion; composicion farmaceutica que contiene a los compuestos; y uso en el tratamiento del dolor agudo, neuropatico o cronico, entre otros.
CO2021010493A2 (es) Compuestos de halo-alilamina y uso de los mismos
CO2023014204A2 (es) Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7)
ECSP19026973A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
ECSP22032016A (es) Inhibidor de irak y método de preparación para el mismo y uso del mismo
CO2022009510A2 (es) Compuestos activos frente a receptores nucleares
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
CL2023000196A1 (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos
CO2023012903A2 (es) Derivados de pirimidina útiles como inhibidores de la proteína cinasa de repetición 2 rica en leucina (lrrk2)
PE20210550A1 (es) Compuestos de 4-metildihidropirimidinona y su uso farmaceutico
UY38006A (es) Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones
UY37412A (es) Compuestos de indazol para uso en lesiones de tendones y/o ligamentos
AR128066A1 (es) Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos
CO2022015428A2 (es) Compuesto de oxofenilarsina deuterada y uso del mismo
UY39625A (es) Derivados tricíclicos útiles como inhibidores de parp7
DOP2021000028A (es) Formulaciones de dendrímeros